Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Tue, 28.05.2024
Evotec SE
Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington’s disease
One of Evotec’s largest strategic drug discovery alliances
Hamburg, Germany, 28 May 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20 [ … ]
Tue, 28.05.2024
Evotec SE
Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington’s disease
One of Evotec’s largest strategic drug discovery alliances
Hamburg, Germany, 28 May 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20 [ … ]
Wed, 22.05.2024
Evotec SE
CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER
STRONG START WITH JUST – EVOTEC BIOLOGICS IN Q1 2024
POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY OF REVENUES TOWARDS END OF THE YEAR
RESET FOR PROFITABLE GROWTH INITIATED, NEW REPORTING SEG [ … ]
Wed, 15.05.2024
Evotec SE
Hamburg, Germany, 15 May 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call [ … ]
Tue, 30.04.2024
Evotec SE
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES
STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS
JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY
Berlin and Hamburg, Germany, 30 April 2024:
Bayer and the German-based l [ … ]
Wed, 24.04.2024
Evotec SE
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE
PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M
EVOTEC’S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST – EVOTEC BIOLOGICS” STARTING Q1 2024
Hamburg, Germany, 24 April 202 [ … ]
Tue, 23.04.2024
Evotec SE
Hamburg, Germany, 23 April 2024:
The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that bega [ … ]
Thu, 18.04.2024
Evotec SE
COLLABORATION LEVERAGES VARIANT BIO’S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC’S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS
COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAMM [ … ]
Wed, 17.04.2024
Evotec SE
Hamburg, Germany, 17 April 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in [ … ]
Wed, 17.04.2024
Evotec SE
Hamburg, Germany, 17 April 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer (“CPO”), effective 15 June 2024. Aurélie will be joining Evotec’s Management Board, bringing with her a wealth of experience and experti [ … ]